Agomab Therapeutics(AGMB)

View 1 open job Website LinkedIn Careers Page

Focus: Agomab Therapeutics is a Belgium-based biotech company specializing in agonistic monoclonal antibody molecules, currently in early-stage clinical development with a focus on immunology and fibrosis indications.

Unknown Immunology

Profile data last refreshed 22h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

Should You Work at Agomab Therapeutics?

AI assessment

Agomab offers a rare opportunity to join a public biotech with differentiated science and early career impact, but limited transparency and pre-revenue status demand confidence in the agonistic mAb platform thesis.

Why Work Here

Leading-edge science: Agonistic mAb platform represents a differentiated modality with only 6 active clinical trials across 3 programs, allowing hands-on ownership of emerging science.

Data completeness

3/9 — Basic

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

1 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

ORG-129

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT04933565First in Human Study of ORG-129 in Healthy Volunteers

Phase 1

Help build intelligence for Agomab Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage growth opportunity: Public company status (ticker: AGMB) with active hiring in Clinical Development suggests expansion phase before major regulatory catalysts.

Focused therapeutic thesis: Concentrated pipeline in high-unmet-need areas (fibrostenotic Crohn's disease, IPF) indicates strategic clarity.

Watch Out For

Minimal commercial infrastructure: Only 4 active job openings and no approved products mean limited revenue generation and potential job security risk if pipeline falters.
Data scarcity: Missing employee count, founding date, funding amounts, financials, and R&D intensity create visibility gaps on company health and sustainability.
Early-stage execution risk: No Phase 3 programs and only 1 Phase 2 trial (AGMB-129) mean 3+ years minimum to meaningful near-term catalysts.

Generated by Claude from Agomab Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

AGMB-447

IPF

Phase 1

Clinical Trials (1)

NCT06181370Phase I Study to Assess Safety, Tolerability, PK and PD of AGMB-447 in Healthy Participants and Participants With IPF

Phase 1

AGMB-129

Fibrostenotic Crohn's Disease

Phase 2

Clinical Trials (4)

NCT05843578STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease

Phase 2

NCT07118878A Multiple Ascending Dose Study With AGMB-129 in Healthy Participants

Phase 1

NCT05937386Drug-Drug Interaction Study With AGMB-129 and Midazolam in Healthy Participants

Phase 1

+1 more

Toxicologic pathology

2021

PMID:33769147

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Agomab Therapeutics(AGMB)

Should You Work at Agomab Therapeutics?

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Open Jobs (1)

Early Commercial Lead - Fibrostenosing Crohn’s Disease

Research Publications(3)